Literature DB >> 21677507

Steroid myopathy: some unresolved issues.

M A Minetto1, F Lanfranco, G Motta, S Allasia, E Arvat, G D'Antona.   

Abstract

Steroid myopathy is a non-inflammatory toxic myopathy that occurs as side effect of exogenous and endogenous glucocorticoid excess. The purpose of this review is to examine issues that limit our understanding of this myopathy with respect to nosology, etiopathogenesis, conditioning factors, and muscle fiber selectivity. We suggest that if more data were available on these issues, the understanding of steroid myopathy would be enhanced substantially, thus allowing an early detection of its occurrence (before the appearance of clinical or laboratory signs) and a proper treatment of the patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21677507     DOI: 10.1007/BF03347462

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  78 in total

1.  Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy.

Authors:  Amanda Jones; Dong-Jin Hwang; Ramesh Narayanan; Duane D Miller; James T Dalton
Journal:  Endocrinology       Date:  2010-06-09       Impact factor: 4.736

2.  Triamcinolone myopathy.

Authors:  R S WILLIAMS
Journal:  Lancet       Date:  1959-04-04       Impact factor: 79.321

Review 3.  Growth hormone axis in cushing's syndrome.

Authors:  B L Wajchenberg; B Liberman; D Giannella Neto; M Y Morozimato; M Semer; L O Bracco; L R Salgado; M Knoepfelmacher; M H Borges; A C Pinto; C E Kater; A M Lengyel
Journal:  Horm Res       Date:  1996

4.  Steroid myopathy. Clinical, histologic and cytologic observations.

Authors:  A K Afifi; R A Bergman; J C Harvey
Journal:  Johns Hopkins Med J       Date:  1968-10

5.  Electron microscopic observations in thyrotoxic and corticosteroid-induced myopathies.

Authors:  A G Engel
Journal:  Mayo Clin Proc       Date:  1966-11       Impact factor: 7.616

Review 6.  Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids?

Authors:  B Robinzon; M Cutolo
Journal:  Rheumatology (Oxford)       Date:  1999-06       Impact factor: 7.580

7.  High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients.

Authors:  T Qian; X Guo; A D Levi; S Vanni; R T Shebert; M L Sipski
Journal:  Spinal Cord       Date:  2005-04       Impact factor: 2.772

8.  Nitric oxide reverses prednisolone-induced inactivation of muscle satellite cells.

Authors:  Jenna L Betters; Jodi H D Long; Kathleen S Howe; Randy W Braith; Quinlyn A Soltow; Vitor A Lira; David S Criswell
Journal:  Muscle Nerve       Date:  2008-02       Impact factor: 3.217

9.  The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene.

Authors:  David S Waddell; Leslie M Baehr; Jens van den Brandt; Steven A Johnsen; Holger M Reichardt; J David Furlow; Sue C Bodine
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-07-08       Impact factor: 4.310

10.  GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1.

Authors:  Daisuke Yamamoto; Nobuko Ikeshita; Takako Matsubara; Hiromitsu Tasaki; Elizabeth Henny Herningtyas; Keizo Toda; Keiji Iida; Yutaka Takahashi; Hidesuke Kaji; Kazuo Chihara; Yasuhiko Okimura
Journal:  Life Sci       Date:  2007-12-05       Impact factor: 5.037

View more
  21 in total

1.  Factors influencing spinal sagittal balance, bone mineral density, and Oswestry Disability Index outcome measures in patients with rheumatoid arthritis.

Authors:  Kazutaka Masamoto; Bungo Otsuki; Shunsuke Fujibayashi; Koichiro Shima; Hiromu Ito; Moritoshi Furu; Motomu Hashimoto; Masao Tanaka; Stephen Lyman; Hiroyuki Yoshitomi; Shimei Tanida; Tsuneyo Mimori; Shuichi Matsuda
Journal:  Eur Spine J       Date:  2017-11-28       Impact factor: 3.134

2.  Glucocorticoid-induced myopathy in the intensive care unit.

Authors:  Heidi Shil Eddelien; Henrik Westy Hoffmeyer; Eva Løbner Lund; Anne Øberg Lauritsen
Journal:  BMJ Case Rep       Date:  2015-05-24

3.  A painful diagnosis.

Authors:  Paolo Fraticelli; Marco Cardinali; Lorenzo Biondi; Devis Benfaremo; Massimo Mattioli; Roberta Mazzucchelli; Rodolfo Montironi; Armando Gabrielli
Journal:  Intern Emerg Med       Date:  2017-02-25       Impact factor: 3.397

4.  Effect of exercise therapy on muscle mass and physical functioning in patients undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  Takahiro Takekiyo; Koichiro Dozono; Takayuki Mitsuishi; Yoshihiro Murayama; Ayako Maeda; Nobuaki Nakano; Ayumu Kubota; Masahito Tokunaga; Shogo Takeuchi; Yoshifusa Takatsuka; Atae Utsunomiya
Journal:  Support Care Cancer       Date:  2014-09-27       Impact factor: 3.603

Review 5.  Diagnostic work-up in steroid myopathy.

Authors:  Marco Alessandro Minetto; Valentina D'Angelo; Emanuela Arvat; Santosh Kesari
Journal:  Endocrine       Date:  2017-11-15       Impact factor: 3.633

Review 6.  Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications.

Authors:  G Arnaldi; T Mancini; G Tirabassi; L Trementino; M Boscaro
Journal:  J Endocrinol Invest       Date:  2012-04       Impact factor: 4.256

7.  Ultrasound-based detection of glucocorticoid-induced impairments of muscle mass and structure in Cushing's disease.

Authors:  M A Minetto; C Caresio; M Salvi; V D'Angelo; N E Gorji; F Molinari; G Arnaldi; S Kesari; E Arvat
Journal:  J Endocrinol Invest       Date:  2018-11-15       Impact factor: 4.256

8.  Alteration in skeletal muscle mass in women with subclinical hypercortisolism.

Authors:  Jae Hyeon Kim; Mi Kyung Kwak; Seong Hee Ahn; Hyeonmok Kim; Yoon Young Cho; Sunghwan Suh; Beom-Jun Kim; Kee-Ho Song; Seung Hun Lee; Jung-Min Koh
Journal:  Endocrine       Date:  2018-05-01       Impact factor: 3.633

9.  Relationship between corticosteroid dose and declines in physical function among allogeneic hematopoietic stem cell transplantation patients.

Authors:  Shinichiro Morishita; Katsuji Kaida; Shinya Yamauchi; Koichiro Sota; Shinichi Ishii; Kazuhiro Ikegame; Norihiko Kodama; Hiroyasu Ogawa; Kazuhisa Domen
Journal:  Support Care Cancer       Date:  2013-03-09       Impact factor: 3.359

Review 10.  How we can mitigate the side effects associated with systemic glucocorticoid after allogeneic hematopoietic cell transplantation.

Authors:  Shigeo Fuji; Michael Byrne; Arnon Nagler; Mohamad Mohty; Bipin N Savani
Journal:  Bone Marrow Transplant       Date:  2021-01-29       Impact factor: 5.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.